EMA Closure Temporarily Delays EC Final Approval Procedures for New Drugs, Including Zepzelca and Joenja
EMA Official Holiday Schedule and Operational Plan
EMA will be officially closed on April 27th (King's Day, a Dutch public holiday) and May 1st (Labor Day). This measure aims to ensure the rest of regulatory agency staff and comply with local labor regulations. During the closure, all general administrative and review tasks will be suspended in principle. However, the Product Emergency Hotline will continue to operate 24/7 to respond promptly to urgent public health crises or drug safety issues. During this period, regulatory documents can be submitted online, but the official submission date and review timeline will resume after the holiday.
Actual Impact on Biotech Regulatory Approval Timelines
This closure, while a simple public holiday, can cause a real delay in timelines for biotech companies with urgent regulatory approval schedules. Since public holidays are excluded when calculating the Review Cycle of a Marketing Authorization Application (MAA) in Europe, key milestone announcements may be delayed by several days. In particular, unlike the U.S. FDA, which has strict deadlines like the Prescription Drug User Fee Act (PDUFA), the EMA has a higher variability in its review schedule depending on national holidays. Therefore, new drug developers about to enter the European market should incorporate this delay period into their risk management, linked to their financial burn rate.
Pharmaceutical Companies' Proactive Risk Management and Response Strategies
Global pharmaceutical and biotech companies are proactively adjusting their document submission schedules to minimize disruptions caused by regulatory agency closures. If the completion of approval reviews or the deadline for submitting Responses to List of Questions (LoQ) falls around the end of April or the beginning of May, they are adopting a strategy of submitting documents a week earlier rather than right before the deadline. This is because failure to coordinate schedules can disrupt the entire commercial launch plan due to delays in communication with regulatory reviewers. This thorough preparation for regulatory risks also serves as an important indicator of a company's operational maturity for institutional investors.
Timeline Risk and Market Impact from an Investment Perspective
From an investor's perspective, the short-term impact of the EMA's closure may seem small, but it can be a source of volatility for specific stocks with pending approval announcements. For example, if the Committee for Medicinal Products for Human Use (CHMP) is scheduled to issue an opinion on a pipeline product at the end of April, even a few days of closure could postpone the opinion to the next meeting. This can disrupt investors' cash flow strategies, especially if it coincides with option expiration dates or quarterly earnings announcements. In the long term, it is expected that this will be an opportunity for regulatory authorities to build automated systems that can ensure business continuity even during holidays through digital transformation.
The European Medicines Agency (EMA) closure will delay the European Commission (EC) final marketing authorization procedures for several new drugs, including those that received positive CHMP opinions in April 2026 (e.g., Palbociclib) and Adstiladrin, which was recommended in March. This will pause the EC approval clock, which typically takes 67 days, and directly affect the commercial launch schedules of smaller biotech companies like Pharming, which holds Joenja for rare diseases. In the medium to long term, the European launch of drugs like Zepzelca, which are in late-stage Phase 3 trials and target the $1 billion small cell lung cancer market, competing with existing standard treatments such as Tecentriq (Roche), may be postponed, requiring adjustments to revenue analysis. As a result, companies need to review their milestone payment schedules linked to regulatory milestones and proactively control the risk of competition for market share with competing drugs. In particular, delays in clinical data approval can negatively impact the valuation of companies that are currently in the process of raising capital or negotiating licensing agreements.